Identification of factors that improve muscle function in boys with Duchenne muscular dystrophy (DMD) could lead to an improved quality of life. To establish a functional in vitro assay for muscle strength, mdx murine myoblasts, the genetic homologue of DMD, were tissue engineered in 96 micro-well plates into three-dimensional muscle constructs with parallel arrays of striated muscle fibers. When electrically stimulated, they generated tetanic forces measured with an automated motion tracking system. Thirtyone compounds of interest as potential treatments for patients with DMD were tested at 3 -6 concentrations. Eleven of the compounds (insulin-like growth factor-1, creatine, β-hydroxy-β-methylbutyrate, trichostatin A, lisinopril, and six from the glucocorticoid family) significantly increased tetanic force relative to placebo-treated controls. The glucocorticoids methylprednisolone, deflazacort, and prednisone increased tetanic forces at low doses (EC 50 of 6 nM, 19 nM, and 56 nM, respectively), indicating a direct muscle mechanism by which they may be benefitting DMD patients. The tetanic force assay also identified beneficial compound interactions (arginine plus deflazacort, prednisone plus creatine) as well as deleterious interactions (prednisone plus creatine inhibited by pentoxifylline) of combinatorial therapies taken by some DMD patients.
INTRODUCTION
Tissue engineering of functional organs as a unique tool for in vitro drug screening applications has been envisioned since the field's early inception (1) (2) (3) . While more complicated than traditional high throughput drug screening (HTS) technologies that use biochemical, gene expression, or single cell assays, the ability to analyze tissue function ex vivo has several advantages. In targeted HTS approaches, it is difficult to predict the ultimate physiological activity of a drug since all compounds have effects on multiple intracellular second messenger pathways (4) . High content drug screening (HCS) with engineered tissues based on tissue function is the culmination of all the complex interactions of compounds on these intracellular pathways, and therefore should be a better predictor of their ultimate in vivo effect at the tissue level.
In addition, the engineering of tissues from diseased animal and human cells allows the screening of new potential drug therapies directly against a specific disease's phenotype. While HCS with engineered tissues will not replace in vivo drug screening, it should serve as a useful secondary follow-on screen to HTS analyses of large compound banks, reducing the time, cost, and animals necessary for in vivo studies.
Physiologic-based HCS technologies assaying skeletal muscle function are under development using nematode worms (5;6), zebrafish (7) and tissue engineered muscle 'organs' (8) . They provide a 'holistic' analysis of a compound's effect on the multiple pathways regulating important physiological parameters of muscle such as strength, fatigability, and contraction-induced injury. To be useful as a primary or secondary drug screen for the analysis of hundreds of compounds, the HCS technologies will require adaptation to the computerized robotic liquid handling
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High Content Drug Screening for Muscular Dystrophy hardware and imaging software developed over the last decade for HTS. This automation has revolutionized HTS, allowing the rapid and reproducible screening of large compound banks. HCS automation will be particularly important in the search for new treatments for diseases such as Duchenne muscular dystrophy (DMD), a progressive, lethal, muscle wasting disease resulting from a defect in the dystrophin gene (9) . Many DMD patients take 'cocktails' of dozens of compounds daily, the complex interactions of which are unknown. While a cure for DMD will ultimately require correction of the defective gene through either gene or cell based therapies, improved therapeutics to attenuate muscle weakness and loss will lead to an enhanced quality and length of life for these patients.
Pharmacological strategies for targeting factors for treating DMD are currently an active area of research. Many compounds tested in the mdx murine model of DMD and/or clinically in patients have either minimal long-term benefits or adverse side effects [reviewed in (10) ]. The most-widely accepted medical treatment in DMD is corticosteroids which have multiple mechanism(s) of action on skeletal muscle in addition to their primary anti-inflammatory role (5;11) . Combinatorial screening by HCS of multiple drugs which have slight beneficial effects when administered separately in DMD may lead to significant progress in the development of new drug protocols or drug 'cocktails' to help patients with this fatal disease (10;11) . In addition, screening chemical banks of FDA approved compounds could lead to the rapid identification of new therapeutic targets for DMD. This paper describes the semi-automation of HCS with skeletal muscle tissue engineered from mdx murine myoblasts in standard 96 micro-well plate format.
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High Content Drug Screening for Muscular Dystrophy Standard HTS liquid handling hardware and software was adapted to automatically tissue engineer miniature BioArtificial Muscles (mdx mBAMs), and customized automated HCS hardware and imaging software was designed to measure muscle strength i.e. tetanic force, generated by the diseased tissues. This is the first report that we are aware of which describes the engineering of tissues with commercially available HTS robotic technology. Compounds of interest as potential strengthening treatment for patients with DMD were tested in a non-destructive manner on mdx mBAM tetanic force at multiple concentrations over a 3-4 day assay period. A number of the compounds were found to have positive effects in a similar manner to their activity in vivo. The HCS mdx mBAM assay also identified a unique mechanism by which glucocorticoids, a commonly used treatment in DMD patients, might attenuate the muscle weakness that is prevalent in the disease. In addition, combinations of these compounds were found to either enhance or reduce the beneficial effects of other compounds on tetanic force.
Tissue engineered contractile tissues may thus be a useful tool for the rapid identification of new compounds for DMD therapy, as well as lead to a better understanding of the complex interactions of the multiple compounds used to improve muscle function, not only in DMD, but potentially in other neuromuscular diseases. When immunocytochemically stained for dystrophin, the myofibers from the control clones were dystrophin positive while those from the mdx clone did not express dystrophin, as previously described (12) .
Tissue Engineering of mdx mBAMs
A 96-microwell plate format for tissue engineering mBAMs was developed that enabled the use of a standard robotic liquid handling system containing 37 (Fig. 1b) . The mBAMs were maintained for 2 days at 39 o C in a humidified 5% CO 2 incubator, switched to differentiation medium (H2KDM: 5% HS, 4 mM glutamine, 100 U/ml penicillin G in DMEM), and maintained in this medium until compound screening was started. The tissue culture media (200 µL/well) was changed daily using the Biomek 2000. 
Statistical Analysis
Means and standard error of the means of four to eight samples per group were calculated and t-test statistical analyses performed using SigmaStat software (Systat Software, Inc.), with a P value of less than 0.05 considered statistically significant.
Power analyses were performed using GraphPad StatMate 2.00 and EC 50 values determined with GraphPad Prism (GraphPad Software, Inc.).
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RESULTS
Passive forces within the coalesced extracellular matrix gel aligned the conditionally immortalized myoblasts parallel to each other in the long axis of the mBAM within the first 24-48 hours of casting, as previously found for primary murine myoblasts (8) . When the mBAMs were then switched to differentiation medium on Day 2 postcasting, the myoblasts fused over the next 6-7 days to form aligned and striated muscle fibers (Fig. 2a -c) . The tetanic forces that the conditionally immortalized control and mdx mBAMs developed were similar in time required to reach a plateau (7-9 days postcasting) and force generated (40 -80 μN) to mBAMs tissue engineered from primary murine myoblasts (8) (Fig. 2d) .
Thirty-one compounds were selected that are either effective in the in vivo mdx murine model for increased muscle strength (13-17) or currently taken by DMD patients for various reasons [ (18) and personal communications from parents of DMD patients].
Each compound was initially tested at three doses and if a trend was evident, 3-4 additional doses were tested. Twenty of the compounds tested were either ineffective or significantly decreased tetanic mdx mBAM force at higher concentrations after two to four days of incubation (Fig. 3) . The compounds ranged from nutraceuticals [Protandim®, Haelan 951, AmSport®, Vital DeTox, resveratrol, (Fig. 3a, k, l, o) ] to antioxidant CoEnzyme Q 10 ( Fig. 3b) , membrane stabilizer Poloxamer 407 (Fig. 3c), anti-hypertensive drug Losartan (Fig. 3d) , creatine metabolite creatinine (Fig. 3e) , amino acids arginine, glycine, alanine, glutamine (Fig. 3e, f, j) , a non-steriodal antiinflammatory drug flurbiprofen (Fig. 3g) , glycosphingolipid biosynthesis inhibitor miglustat (19) (Fig. 3n) , phosphodiesterase inhibitor sildenafil (Fig. 3m) , and the antifibrotic drugs pentoxifylline and ursodeoxycholic acid (Fig. 3h, i) . At high Eleven compounds directly increased mdx mBAM tetanic force including the growth factor insulin-like growth factor-1 (IGF-1, Fig. 4a ), the energy source creatine (Fig. 4b) , histone deacetylase inhibitor trichostatin A (Fig. 4c) , anti-inflammatory glucocorticoids prednisone, Solu-Medrol (methylprednisolone), deflazacort, prednisolone, cortisol, and their parent compound cholesterol (Fig. 4d, e) . Trichostatin A at 0.2 μM resulted in a large increase in mdx mBAM tetanic force (108%) but had a very narrow window of activity and was highly inhibitory at higher concentrations (>3 μM) (Fig. 4c) . All of the glucocorticoids significantly increased mdx mBAM tetanic force at 0.1 μM and were active through 10 μM, with the exception of deflazacort which showed a steeper decline in activity at high doses (Fig. 4d, e) . Half maximal effective concentration (EC 50 ) values for methylprednisolone, deflazacort, and prednisone for tetanic force increases were 6 nM, 19 nM and 56 nM, respectively. The nutraceutical Juven® increased mdx mBAM tetanic force and this appeared to be due to one of its ingredients, β-hydroxy-β-methylbutyrate, which showed a similar dose-response curve (Figure 4f) . The angiotensin-converting enzyme inhibitor lisinopril also significantly increased tetanic force (Figure 4g ). The glucocorticoids methylprednisolone (Solu-Medrol) and deflazacort at 0.80 μM and 0.080 μM, respectively, rapidly increased mdx mBAM tetanic force within 24 hours of addition ( Fig.   5a ) while trichostatin A showed a slower rate of activity, requiring several days to reach statistical significance (Figure 5b) . Four of the positive compounds (IGF-1, methylprednisolone, deflazacort, and prednisone) were tested with non-dystrophic on mdx mBAM tetanic force (Fig. 3f) , but nearly doubled the increase in tetanic force seen with the optimal concentration of deflazacort (0.08 μM) (Fig. 6a) . Similar synergistic interactions occurred with another glucocorticoid (prednisone), when combined with creatine as an energy source (Fig. 6b) . Conversely, a recent clinical trial showed no improvement in muscle strength in prednisone-treated DMD patients when also treated for 12 months with the anti-fibrotic drug pentoxifylline (21); likewise in mdx mBAMs, there was no improvement seen in prednisone-stimulated tetanic force with pentoxifylline ( Fig. 6b) . Interestingly, pentoxifylline completely inhibited the synergistic effect seen with prednisone and creatine (Fig. 6b) . Similarly, another anti-fibrotic drug, ursodeoxycholic acid (Fig. 3i) at 100 μM, completely blocked the synergistic effect of 
